Drug Trial Radar · NCT03459170
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
Last checked: Nov 19, 2026Latest source record: Jul 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Feb 1, 2018
Primary completion
Sep 2022
Study completion Sep 2035
Sponsor
- Lead sponsor
- Bellicum PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The study will consist of the Main Study and an optional Pharmacokinetics (PK) Sub-Study.
Conditions
- Hematologic Malignancy
Interventions
BPX-501 T cellsBiological
Biological: T cells transduced with CaspaCIDe® safety switch
rimiducidDrug
administered to eliminate BPX-501 cells in the event of GVHD
Primary outcomes
What the sponsor says the trial is designed to measure.
- BPX-501 SafetyTime frame: Month 24
- Mean plasma concentrationTime frame: pre-dose, 30 min, 2 hours and 8 hours after start of infusion
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
San Matteo Hospital
Pavia, Italy
IRCCS Ospedale Pediatrico Bambino Gesù
Rome, Italy
Ospedale Infantile Regina Margherita
Turin, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.